Grufity logoGrufity logo

Twist Bioscience Corp Stock Research

TWST

16.18USD+0.20(+1.25%)Market Closed

Market Summary

USD16.18+0.20
Market Closed
1.25%

TWST Alerts

TWST Stock Price

TWST RSI Chart

TWST Valuation

Market Cap

916.5M

Price/Earnings (Trailing)

-4.28

Price/Sales (Trailing)

4.25

EV/EBITDA

-3.07

Price/Free Cashflow

-3.94

TWST Price/Sales (Trailing)

TWST Profitability

Operating Margin

43.59%

EBT Margin

-99.20%

Return on Equity

-28.69%

Return on Assets

-23.53%

Free Cashflow Yield

-25.39%

TWST Fundamentals

TWST Revenue

Revenue (TTM)

215.8M

Revenue Y/Y

29.09%

Revenue Q/Q

-5.34%

TWST Earnings

Earnings (TTM)

-214.1M

Earnings Y/Y

8.21%

Earnings Q/Q

18.18%

Price Action

52 Week Range

14.9858.76
(Low)(High)

Last 7 days

-3.6%

Last 30 days

-22.3%

Last 90 days

-30.2%

Trailing 12 Months

-65.9%

TWST Financial Health

Current Ratio

6.46

TWST Investor Care

Shares Dilution (1Y)

13.49%

Diluted EPS (TTM)

-3.84

Peers (Alternatives to Twist Bioscience)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
127.1B
26.3B
0.79% 2.78%
19.4
4.83
1.32% 11.18%
99.8B
27.3B
-4.19% 39.66%
21.72
3.66
-0.09% -26.23%
58.1B
19.3B
-4.61% -16.03%
6.95
3.02
4.29% -31.47%
39.0B
10.2B
-0.92% 26.77%
12.8
3.83
-7.36% 95.80%
MID-CAP
9.4B
1.5B
-5.59% 3.19%
60.62
6.29
31.34% 72.43%
3.1B
108.5M
-21.66% -32.82%
-9.55
28.71
122.90% -12.19%
2.2B
107.9M
21.83% 38.60%
-4.63
20.79
54.84% 17.36%
2.2B
60.9M
-25.55% -48.21%
-7.49
35.56
17.51% 22.00%
SMALL-CAP
1.3B
112.0M
-7.70% -49.25%
-4.81
11.47
-70.76% -603.77%
1.1B
7.0M
-17.00% 22.02%
-7.14
159.78
131.81% -45.39%
524.4M
96.3M
-14.58% -86.07%
-1.86
5.45
72.44% -32.79%
519.7M
2.0B
-33.63% -92.58%
-0.79
0.26
72.89% 62.27%
276.9M
111.3M
-42.96% -71.96%
-1.44
2.49
0.54% -7.86%
101.6M
107.0K
-17.23% -85.52%
-0.94
949.93
-88.00% -52.91%
26.0M
-
40.00% -84.44%
-0.32
3.21
0.51% -185.61%

Financials for Twist Bioscience

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue6.0%215,789,000203,565,000184,209,000163,114,000146,191,000
  S&GA Expenses-4.1%204,174,000212,949,000197,032,000177,817,000158,208,000
  R&D Expenses7.2%128,919,000120,307,000110,144,00093,142,00077,702,000
EBITDA7.7%-195,356,000-211,694,000-204,221,000-187,549,000-
EBITDA Margin12.9%-0.91-1.04-1.11-1.15-
Earnings Before Taxes6.2%-214,054,000-228,274,000-218,352,000-200,100,000-177,141,000
EBT Margin11.5%-0.99-1.12-1.19-1.23-
Interest Expenses-30.0%56,00080,000138,000208,000274,000
Net Income1.7%-214,124,000-217,863,000-207,990,000-187,510,000-164,761,000
Net Income Margin7.3%-0.99-1.07-1.13-1.15-
Free Cahsflow-2.9%-232,700,000-226,242,000-251,405,000-211,540,000-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-5.3%9109619801,022786
  Current Assets-9.2%542596624664385
    Cash Equivalents-16.4%317379376408193
  Inventory13.5%45.0039.0043.0045.0040.00
  Net PPE3.9%14513912792.0065.00
  Goodwill0%86.0086.0086.0086.0084.00
Liabilities-4.9%164172159158160
  Current Liabilities-7.5%84.0091.0093.0085.0080.00
    LT Debt, CurrentNaN%-----
Shareholder's Equity-5.5%746789821863626
  Retained Earnings-5.0%-870-828-777-716-656
  Additional Paid-In Capital-0.2%1,6171,6201,5991,5811,282
Shares Outstanding0.2%57.0057.0056.0056.0050.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-6.0%-131-124-157-151-133
  Share Based Compensation-25.6%59.0080.0070.0059.0048.00
Cashflow From Investing94.3%-13.32-232-211-111-24.51
Cashflow From Financing0.2%2712712712711.00

Risks for TWST

What is the probability of a big loss on TWST?

97.4%


Probability that Twist Bioscience stock will be more than 20% underwater in next one year

97.0%


Probability that Twist Bioscience stock will be more than 30% underwater in next one year.

63.8%


Probability that Twist Bioscience stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does TWST drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Twist Bioscience was unfortunately bought at previous high price.

Drawdowns

Returns for TWST

Cumulative Returns on TWST

-15.4%


3-Year Cumulative Returns

Which funds bought or sold TWST recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
sold off
-100
-250,000
-
-%
2023-03-10
BAILLIE GIFFORD & CO
added
21.84
-5,550,360
25,847,600
0.03%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
sold off
-100
-10,620,000
-
-%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-81.99
-840,000
116,000
-%
2023-02-28
Voya Investment Management LLC
added
0.71
-17,552,400
37,376,600
0.05%
2023-02-24
NATIXIS
sold off
-100
-2,892,000
-
-%
2023-02-21
MACQUARIE GROUP LTD
reduced
-43.51
-379,000
220,000
-%
2023-02-16
HARBOUR INVESTMENTS, INC.
new
-
500
500
-%
2023-02-15
Point72 Middle East FZE
new
-
15,929
15,929
-%
2023-02-15
Virtu Financial LLC
added
142
151,000
388,000
0.05%

1–10 of 42

Latest Funds Activity

Are funds buying TWST calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own TWST
No. of Funds

Twist Bioscience News

Seeking Alpha

AbCellera: Why I Don't Love This Drug Discoverer's Business Model ....

Seeking Alpha,
43 hours ago

InvestorsObserver

Seeking Alpha

Schedule 13G FIlings of Twist Bioscience

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2023
capital world investors
1.2%
704,000
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
9.24%
5,229,345
SC 13G/A
Feb 03, 2023
state street corp
7.82%
4,426,249
SC 13G
Feb 03, 2023
sumitomo mitsui trust holdings, inc.
5.18%
2,934,033
SC 13G
Jan 24, 2023
blackrock inc.
9.7%
5,487,180
SC 13G/A
Jan 13, 2023
jpmorgan chase & co
6.7%
3,829,962
SC 13G
Jun 09, 2022
ark investment management llc
11.14%
6,267,721
SC 13G/A
Mar 10, 2022
fmr llc
-
0
SC 13G
Feb 11, 2022
capital world investors
8.9%
4,522,700
SC 13G/A

TWST Fair Value

Twist Bioscience fair value in different scenarios

The table shows the Fair Value estimates for Twist Bioscience for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

3.95

-75.59%

4.74

-70.70%

7.37

-54.45%

12.04

-25.59%

21.39

32.20%
Current Inflation

3.89

-75.96%

4.60

-71.57%

6.89

-57.42%

10.91

-32.57%

18.90

16.81%
Very High Inflation

3.82

-76.39%

4.43

-72.62%

6.33

-60.88%

9.58

-40.79%

16.01

-1.05%

Historical Twist Bioscience Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Twist Bioscience

View All Filings
Date Filed Form Type Document
Mar 21, 2023
4
Insider Trading
Mar 21, 2023
4
Insider Trading
Mar 21, 2023
4
Insider Trading
Mar 21, 2023
4
Insider Trading
Mar 21, 2023
4
Insider Trading
Mar 15, 2023
4
Insider Trading
Mar 15, 2023
4
Insider Trading
Feb 22, 2023
4
Insider Trading
Feb 22, 2023
4
Insider Trading
Feb 22, 2023
4
Insider Trading

Latest Insider Trading transactions for TWST

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-17
Cho Dennis
sold (taxes)
-4,210
16.51
-255
see remarks
2023-03-17
Leproust Emily M.
sold (taxes)
-28,859
16.51
-1,748
chief executive officer
2023-03-17
Banyai William
sold (taxes)
-6,901
16.51
-418
see remarks
2023-03-17
Green Paula
sold (taxes)
-3,962
16.51
-240
svp of human resources
2023-03-17
THORBURN JAMES M
sold (taxes)
-8,981
16.51
-544
chief financial officer
2023-03-13
Cho Dennis
sold (taxes)
-1,733
16.83
-103
see remarks
2023-02-17
Yankton Kevin Bruce
sold (taxes)
-1,351
22.52
-60.00
chief accounting officer
2023-02-17
Finn Patrick John
sold (taxes)
-23,128
22.52
-1,027
president and coo
2023-02-17
Leproust Emily M.
sold (taxes)
-61,727
22.52
-2,741
chief executive officer
2023-02-17
THORBURN JAMES M
sold (taxes)
-23,128
22.52
-1,027
chief financial officer

1–10 of 50

Emily M. Leproust
650
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.

TWST Income Statement

2022-09-30
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Statement of Comprehensive Income [Abstract]   
Revenues$ 203,565$ 132,333$ 90,100
Operating expenses:   
Cost of revenues119,33080,62061,406
Research and development120,30769,07243,006
Selling, general and administrative212,949135,901103,267
Change in fair value of contingent considerations and holdbacks(14,245)(534)0
Litigation settlement0022,500
Total operating expenses438,341285,059230,179
Loss from operations(234,776)(152,726)(140,079)
Interest income3,0624351,499
Interest expense(80)(367)(787)
Gain on deconsolidation of subsidiary4,60700
Other income (expense), net(1,087)(1,370)(182)
Loss before income taxes(228,274)(154,028)(139,549)
Benefit from (provision for) income taxes10,4111,930(382)
Net loss attributable to common stockholders(217,863)(152,098)(139,931)
Other comprehensive loss:   
Change in unrealized gain (loss) on investments(1,594)(14)(34)
Foreign currency translation adjustment(795)473(60)
Comprehensive loss$ (220,252)$ (151,639)$ (140,025)
Net loss per share attributable to common stockholders—basic (in dollars per share)$ (4.04)$ (3.15)$ (3.57)
Net loss per share attributable to common stockholders—diluted (in dollars per share)$ (4.04)$ (3.15)$ (3.57)
Weighted average shares used in computing net loss per share attributable to common stockholders—basic (in shares)53,88548,25139,190
Weighted average shares used in computing net loss per share attributable to common stockholders—diluted (in shares)53,88548,25139,190

TWST Balance Sheet

2022-09-30
Consolidated Balance Sheets - USD ($)
Sep. 30, 2022
Sep. 30, 2021
Current assets:  
Cash and cash equivalents$ 378,687,000$ 465,829,000
Short-term investments126,281,00012,034,000
Accounts receivable, net40,294,00028,549,000
Inventories39,307,00031,800,000
Prepaid expenses and other current assets11,914,0008,283,000
Total current assets596,483,000546,495,000
Property and equipment, net139,441,00044,122,000
Operating lease right-of-use assets74,948,00061,580,000
Goodwill85,811,00022,434,000
Intangible assets, net59,738,00018,262,000
Restricted cash, non-current1,572,0001,530,000
Other non-current assets3,385,0007,674,000
Total assets961,378,000702,097,000
Current liabilities:  
Accounts payable20,092,00014,900,000
Accrued expenses10,169,0006,437,000
Accrued compensation27,023,00022,327,000
Current portion of operating lease liability13,642,0008,213,000
Current portion of long-term debt01,552,000
Other current liabilities19,737,0009,623,000
Total current liabilities90,663,00063,052,000
Operating lease liability, net of current portion81,270,00053,156,000
Other non-current liabilities60,0005,068,000
Total liabilities171,993,000121,276,000
Commitments and contingencies
Stockholders’ equity  
Common stock, $0.00001 par value — 100,000 and 100,000 shares authorized at September 30, 2022 and 2021, respectively; 56,523 and 49,499 shares issued and outstanding at September 30, 2022 and 2021, respectively00
Additional paid-in capital1,619,644,0001,190,828,000
Accumulated other comprehensive (loss)/income(1,843,000)546,000
Accumulated deficit(828,416,000)(610,553,000)
Total stockholders’ equity789,385,000580,821,000
Total liabilities and stockholders’ equity$ 961,378,000$ 702,097,000